Mink's inkt cell therapy shows potential for optimal multi-combination for resistant solid cancers at sitc 2024

Agent-797 combination with checkpoint inhibitors and bispecific engagers expands anti-cancer benefit prame-tcr inkt overcomes challenges from conventional tcr-t cells in solid cancers new york, nov. 07, 2024 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster presentations at the society for immunotherapy of cancer's (sitc) 39th annual meeting in houston, texas. the presentations showcased new data from mink's inkt cell therapy programs, agent-797 and prame-tcr.
INKT Ratings Summary
INKT Quant Ranking